Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer.
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading include Zymeworks (NASDAQ: ZYME), Olema Pharmaceuticals (NASDAQ: OLMA), Brand Engagement Network (NASDAQ: BNAI), Aura Biosciences (NASDAQ: AURA), Tevogen Bio Holdings (NASDAQ: TVGN), ArcelorMittal SA (NYSE: MT), Invivyd (NASDAQ: IVVD), ORIC Pharmaceuticals (NASDAQ: ORIC), York Space Systems (NYSE: YSS), and Heartland Express (NASDAQ: HTLD).
ORIC Pharmaceuticals reports Q2 2025 results with a wider loss but extends cash runway to 2H 2028. Updates on ORIC-944 and enozertinib show progress in oncology trials.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
